Published Articles On Melorheostosis
Read below for recent publications. For more information on the National Institutes of Health study publications, click below.
The Melorheostoses | Genetics of Bone Biology and Skeletal Disease (Third Edition)
Michael P. Whyte, Smita Jha, Joan C. Marini, Timothy BhattacharyyaAbstract: Melorheostosis is the term devised a century ago for this ultrarare dysostosis characterized by thickened skeletal cortex often said to resemble candle wax that dripped along the surface of one or more bones. Now, genomic studies have revealed that melorheostosis is caused by postzygotic somatic mutation of the genes MAP2K1, SMAD3, or KRAS, but sometimes involves germline mutation of LEMD3. Genotype/phenotype differences have emerged. Herein, we begin by reviewing the discovery, clinical, and laboratory features, and orthopedic treatment experience concerning “generic melorheostosis” and briefly recount past speculation about its etiology and pathogenesis. Then, we detail the discoveries and delineation of the individual types of melorheostosis and what they reveal, bearing on the genetics of bone biology and skeletal disease.
Progress towards drug treatment for melorheostosis
Wordsworth, PWordsworth highlights the growing progress toward developing targeted drug treatments for melorheostosis, driven by discoveries that many cases are caused by changes in the MAP2K1 gene and the signaling pathways that control abnormal bone growth. While no disease-specific medication is currently approved, advances in understanding the biology of melorheostosis are bringing researchers closer to therapies that could slow or prevent disease progression rather than simply managing symptoms.
Melorheostosis: Clinical, radiological, and histopathological features with a literature review
Koca, E, Kavak, Ş, Demir, B, Comunoglu, N, Kantarci, F, & Koca, OThis case report and literature review highlights how melorheostosis can mimic more common bone disorders, leading to delayed or incorrect diagnoses, and emphasizes the importance of combining clinical evaluation with advanced imaging to reach an accurate diagnosis. The authors also summarize current knowledge of the disease, including its characteristic radiologic and histopathologic features, recent genetic discoveries involving MAP2K1 and SMAD3, and the need for targeted treatment strategies and greater clinical awareness.
Melorheostosis: A Systematic Review of Clinical Manifestations, Diagnostic Challenges, Therapeutic Strategies, and Physiotherapeutic Interventions
Deshmukh NS, Phansopkar PAnalyzes five studies involving 423 patients with melorheostosis and found that the disease most commonly causes pain, stiffness, deformity, and reduced mobility, while diagnosis remains challenging because its imaging features often overlap with other bone disorders. Conservative treatments—including pain management and structured physiotherapy focused on stretching, strengthening, and pacing—were shown to improve function and quality of life, whereas surgery may be necessary for severe deformities but carries a high risk of recurrence, highlighting the need for standardized treatment approaches and further research into the disease’s genetic basis.
Developing a standard dataset in the European registries for rare endocrine and bone conditions-a Melorheostosis dataset
Appelman-Dijkstra, N.M., Cherenko, M., Clunie, G.P.R. et al.Researchers from the European Registries for Rare Endocrine and Bone Conditions (EuRREB) developed the first standardized international dataset for melorheostosis, creating a consistent way to collect clinical information from patients across Europe. This common dataset will improve collaboration among researchers and clinicians, helping advance our understanding of the disease and accelerate future research into better diagnosis, treatment, and care.
Melorheostosis: A Review of the Literature and a Case Report
Iordache S, Cursaru A, Serban B, Costache M, Spiridonica R, Cretu B, Cirstoiu CA comprehensive overview of melorheostosis, covering its clinical presentation, characteristic “dripping candle wax” radiographic appearance, genetic discoveries, and current treatment options. Through a detailed patient case study and literature review, the authors highlight the challenges of diagnosing and managing this rare bone disease and emphasize the need for multidisciplinary care and continued research into targeted therapies.
Osteoblast Dysfunction in Non-Hereditary Sclerosing Bone Diseases
Giardullo L, Altomare A, Rotondo C, Corrado A, Cantatore FPStudy summarizes how abnormal osteoblast (bone-forming cell) signaling drives rare non-hereditary sclerosing bone diseases, including melorheostosis, highlighting the role of somatic mutations in the MAPK pathway—particularly MAP2K1—that disrupt normal bone formation and lead to excessive bone growth. The authors conclude that a better understanding of these cellular pathways could identify new targeted therapies for melorheostosis and related disorders, although much more research is needed to translate these discoveries into treatments.
A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis
De Ridder R, Boudin E, Zillikens MC, Ibrahim J, van der Eerden BCJ, Van Hul W, Mortier GUsing genomic, transcriptomic, and molecular analyses this study identified new disease-causing MAP2K1 mutations in patients with melorheostosis, expanding the known genetic spectrum of the disorder. The findings confirmed that activating mutations in different regions of the MAP2K1 gene can drive abnormal bone growth and suggested that additional, yet unidentified genetic causes may exist in patients without known mutations.
Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis
Wordsworth P, Chan MSummarizes the clinical features, imaging findings, genetics, and treatment approaches for both melorheostosis and osteopoikilosis, highlighting major advances in understanding these rare bone disorders. The authors emphasized the discovery of somatic MAP2K1 and KRAS mutations in melorheostosis, which has transformed knowledge of the disease and may pave the way for targeted therapies in the future.
Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS
Whyte MP, Griffith M, Trani L, Mumm S, Gottesman GS, McAlister WH, Krysiak K, Lesurf R, Skidmore ZL, Campbell KM, Rosman IS, Bayliss S, Bijanki VN, Nenninger A, Van Tine BA, Griffith OL, Mardis ERIdentifies a somatic activating KRAS mutation in skin tissue overlying melorheostotic bone lesions, providing strong evidence that postzygotic mosaicism can cause certain forms of melorheostosis. The findings expanded the understanding of the disease beyond previously known genetic causes and suggested that mutations in the RAS/MAPK signaling pathway play an important role in abnormal bone and skin development.